Oncology · Gastroenterology · 2 h ago
Claudin-4 identified as receptor for a colorectal cancer-linked bacterial toxin
A Nature study used genome-wide CRISPR screening and molecular binding experiments to identify claudin-4 as the receptor for Bacteroides fragilis toxin (BFT). A claudin-4-based molecular decoy protected mice from toxin-induced intestinal damage, but cancer prevention and safety in humans have not been tested.
- Claudin-4 enables BFT binding to colon epithelial cells.
- A claudin-4-based decoy protected mice from toxin-induced damage.
- Human safety and cancer-prevention effects remain untested.
Researchers led by Johns Hopkins investigators used genome-wide CRISPR screening in colon epithelial cells to identify genes required for BFT, produced by some strains of Bacteroides fragilis, to bind and damage cells. Claudin-4 emerged as the key receptor. Laboratory binding experiments, conducted with collaborators at the Molecular Biology Institute of Barcelona, provided evidence that BFT and claudin-4 form a complex. BFT binding enables the toxin to damage E-cadherin, which helps maintain the epithelial barrier.
The team then developed a soluble protein decoy containing claudin-4 sequences. In mouse experiments, BFT bound to the decoy rather than cell-surface claudin-4, and the decoy protected against toxin-induced intestinal damage.
The findings identify a possible target for strategies to block BFT activity, which has been linked to inflammation and tumor formation. However, the experiments do not show that the decoy prevents colorectal cancer, and its safety and efficacy in people are unknown. The researchers also have not resolved the exact three-dimensional structure of the BFT–claudin-4 interaction. The study received partial support from the National Institutes of Health.
In practice
This study does not support a change in colorectal cancer prevention or treatment. It identifies claudin-4 as the receptor used by B. fragilis toxin and shows that a claudin-4-based decoy can protect mice from toxin-induced intestinal damage. The decoy remains an experimental approach: the reported work does not establish prevention of colorectal cancer, safety or efficacy in humans, or a clinically usable intervention. The findings are mechanistic and preclinical.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature (via ScienceDaily): Scientists finally discover how a common gut bacterium can trigger colon cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.